HRMY - Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania.

52W High

$41.61

52W Low

$26.47

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.84

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

11.61

Forward P/E (<15 better)

8.82

EV/EBITDA (<8 favorable)

6.33

EV/Revenue (<3 favorable)

2.17

P/S (TTM) (<3 favorable)

2.68

P/B (<3 favorable)

2.68

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

11.04%

Institutions (25–75% balanced)

95.02%

Shares Outstanding

57,533,000

Float

50,652,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

772,527,000

Gross Profit (TTM)

605,193,000

EPS (TTM)

3.10

Profit Margin (>10% good)

0.23%

Operating Margin (TTM) (higher better)

0.24%

ROE (TTM) (>15% strong)

0.28%

EPS YoY (Quarterly) (>10% good)

2.40

Revenue YoY (Quarterly) (>8% good)

0.16

Momentum

Bearish momentum

Value

-0.8217

-0.5559

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025